Cargando…

Ocular Barriers and Their Influence on Gene Therapy Products Delivery

The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclercq, Bastien, Mejlachowicz, Dan, Behar-Cohen, Francine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143174/
https://www.ncbi.nlm.nih.gov/pubmed/35631584
http://dx.doi.org/10.3390/pharmaceutics14050998
_version_ 1784715740676358144
author Leclercq, Bastien
Mejlachowicz, Dan
Behar-Cohen, Francine
author_facet Leclercq, Bastien
Mejlachowicz, Dan
Behar-Cohen, Francine
author_sort Leclercq, Bastien
collection PubMed
description The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to maintain the ocular homeostasis. Specialized junctions between the cells of different tissues have specific features which guarantee sealing properties and selectively control the passage of drugs from the circulation or the outside into the tissues and within the different ocular compartments. Tissues structure also constitute selective obstacles and pathways for various molecules. Specific transporters control the passage of water, ions, and macromolecules, whilst efflux pumps reject and eliminate toxins, metabolites, or drugs. Ocular barriers, thus, limit the bioavailability of gene therapy products in ocular tissues and cells depending on the route chosen for their administration. On the other hand, ocular barriers allow a real local treatment, with limited systemic side-effects. Understanding the different barriers that limit the accessibility of different types of gene therapy products to the different target cells is a prerequisite for the development of efficient gene delivery systems. This review summarizes actual knowledge on the different ocular barriers that limit the penetration and distribution of gene therapy products using different routes of administration, and it provides a general overview of various methods used to bypass the ocular barriers.
format Online
Article
Text
id pubmed-9143174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91431742022-05-29 Ocular Barriers and Their Influence on Gene Therapy Products Delivery Leclercq, Bastien Mejlachowicz, Dan Behar-Cohen, Francine Pharmaceutics Review The eye is formed by tissues and cavities that contain liquids whose compositions are highly regulated to ensure their optical properties and their immune and metabolic functions. The integrity of the ocular barriers, composed of different elements that work in a coordinated fashion, is essential to maintain the ocular homeostasis. Specialized junctions between the cells of different tissues have specific features which guarantee sealing properties and selectively control the passage of drugs from the circulation or the outside into the tissues and within the different ocular compartments. Tissues structure also constitute selective obstacles and pathways for various molecules. Specific transporters control the passage of water, ions, and macromolecules, whilst efflux pumps reject and eliminate toxins, metabolites, or drugs. Ocular barriers, thus, limit the bioavailability of gene therapy products in ocular tissues and cells depending on the route chosen for their administration. On the other hand, ocular barriers allow a real local treatment, with limited systemic side-effects. Understanding the different barriers that limit the accessibility of different types of gene therapy products to the different target cells is a prerequisite for the development of efficient gene delivery systems. This review summarizes actual knowledge on the different ocular barriers that limit the penetration and distribution of gene therapy products using different routes of administration, and it provides a general overview of various methods used to bypass the ocular barriers. MDPI 2022-05-06 /pmc/articles/PMC9143174/ /pubmed/35631584 http://dx.doi.org/10.3390/pharmaceutics14050998 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Leclercq, Bastien
Mejlachowicz, Dan
Behar-Cohen, Francine
Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title_full Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title_fullStr Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title_full_unstemmed Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title_short Ocular Barriers and Their Influence on Gene Therapy Products Delivery
title_sort ocular barriers and their influence on gene therapy products delivery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9143174/
https://www.ncbi.nlm.nih.gov/pubmed/35631584
http://dx.doi.org/10.3390/pharmaceutics14050998
work_keys_str_mv AT leclercqbastien ocularbarriersandtheirinfluenceongenetherapyproductsdelivery
AT mejlachowiczdan ocularbarriersandtheirinfluenceongenetherapyproductsdelivery
AT beharcohenfrancine ocularbarriersandtheirinfluenceongenetherapyproductsdelivery